Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma

NCT00193973 is registered in ClinicalTrials.gov with Trans Tasman Radiation Oncology Group as lead sponsor.

NCT NCT00193973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00193973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma
Lead sponsor
Trans Tasman Radiation Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2001
Completion date
August 31, 2013
Enrollment
20 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system lymphoma